Kansas City, KS – According to filings with the U.S. Securities and Exchange Commission, Cingulate is raising $220,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Louis VanHorn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cingulate
Cingulate is a biopharmaceutical company utilizing its innovative Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products. We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), we believe there are multiple therapeutic areas where our PTR technology may be employed to develop additional product candidates, notably anxiety disorders.

To learn more about Cingulate, visit http://www.cingulate.com/

Contact:
Louis VanHorn, Chief Financial Officer
913-942-2300
lvanhorn@cingulatetherapeutics.com
https://www.linkedin.com/in/louvanhorn/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved